{"id":"NCT01623531","sponsor":"Nova Scotia Health Authority","briefTitle":"Prospective Double Blinded Randomized Control Study of the Use of Fibrinogen in High-Risk Cardiac Surgery","officialTitle":"The Use of Fibrinogen Concentrate in High-Risk Cardiac Surgery. A Prospective, Double-blinded, Randomized, Controlled Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02","primaryCompletion":"2019-03-31","completion":"2019-06-30","firstPosted":"2012-06-20","resultsPosted":"2020-05-22","lastUpdate":"2020-05-22"},"enrollment":62,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Cardiac Complication During Procedure"],"interventions":[{"type":"DRUG","name":"Fibrinogen","otherNames":["RiaSTAP or Haemocomplettan P"]}],"arms":[{"label":"RiaSTAP","type":"ACTIVE_COMPARATOR"},{"label":"Intravenous saline","type":"PLACEBO_COMPARATOR"}],"summary":"The aim of the study is to show that first line treatment with concentrated fibrinogen has superiority over the conventional therapy with fresh frozen plasma (FFP), platelets, and cryoprecipitate in perioperative management of bleeding after complex cardiac surgery.","primaryOutcome":{"measure":"Cumulative Transfusion Units","timeFrame":"24 hours after administration of study drug","effectByArm":[{"arm":"RiaSTAP","deltaMin":0,"sd":null},{"arm":"Intravenous Saline","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":".908"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":14},"locations":{"siteCount":1,"countries":["Canada"]},"refs":{"pmids":["31889306"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":27},"commonTop":["Incisional wound infection"]}}